

Oliver Patschan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/377358/publications.pdf>

Version: 2024-02-01

26
papers

1,714
citations

567281

15
h-index

610901

24
g-index

29
all docs

29
docs citations

29
times ranked

2460
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to Amit Bansal, Ruchir Maheshwari, and Anant Kumar's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. <i>Eur Urol</i> 2020;78:757-63. <i>European Urology</i> , 2021, 79, e79-e80.	1.9	0
2	Reply to Deepansh Dalela, Isaac Palma-Zamora, and Craig Rogers's Letter to the Editor re: Fredrick Leidberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. <i>Eur Urol</i> 2020;78:757-63. <i>European Urology</i> , 2021, 79, e117-e118.	1.9	0
3	Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra. <i>Bladder Cancer</i> , 2021, 7, 213-220.	0.4	0
4	Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 2636-2647.	5.1	56
5	Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. <i>European Urology</i> , 2020, 78, 757-763.	1.9	31
6	Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.07.033 . <i>European Urology</i> , 2020, 78, e186-e187.	1.9	0
7	Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients. <i>Scandinavian Journal of Urology</i> , 2019, 53, 109-115.	1.0	8
8	Long-term functional outcomes after radical cystectomy with ileal bladder substitute: does the definition of continence matter?. <i>Scandinavian Journal of Urology</i> , 2017, 51, 44-49.	1.0	5
9	Second-look resection for primary stage T1 bladder cancer: a population-based study. <i>Scandinavian Journal of Urology</i> , 2017, 51, 301-307.	1.0	15
10	[¹⁸ F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 308-313.	1.0	29
11	Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 606.e9-606.e16.	1.6	30
12	A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 824-832.	1.9	111
13	Transurethral Bladder Tumor Resection Can Cause Seeding of Cancer Cells into the Bloodstream. <i>Journal of Urology</i> , 2015, 193, 53-57.	0.4	69
14	Does Incision Length Matter? Robotic Assisted Extracorporeal Urinary Diversion via Mini-laparotomy Using the Alexis O-ring Retractor. <i>European Urology</i> , 2015, 67, 179-180.	1.9	1
15	Use of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort. <i>Scandinavian Journal of Urology</i> , 2015, 49, 127-132.	1.0	11
16	Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based Swedish National Cohort Study with Matched General Population Comparator Subjects. <i>PLoS ONE</i> , 2014, 9, e113602.	2.5	19
17	Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors11Grant support: The Swedish Cancer Society, the Swedish research council, the Nilsson Cancer foundation, the BioCARE Strategic Cancer Research program, the Lund Medical Faculty, and FoU Landstinget Kronoberg and SÄdra Region. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 791-797.	1.6	106
18	Toward a Molecular Pathologic Classification of Urothelial Carcinoma. <i>American Journal of Pathology</i> , 2013, 183, 681-691.	3.8	155

#	ARTICLE	IF	CITATIONS
19	Bladder cancer discussed in the internet: a systematic analysis of gender differences of initial posters on an online discussion board. SpringerPlus, 2013, 2, 445.	1.2	2
20	A Molecular Taxonomy for Urothelial Carcinoma. Clinical Cancer Research, 2012, 18, 3377-3386.	7.0	729
21	DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics, 2012, 7, 858-867.	2.7	44
22	Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. World Journal of Urology, 2012, 30, 785-794.	2.2	10
23	Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma. PLoS ONE, 2012, 7, e38863.	2.5	167
24	Clinical experience with survivin as a biomarker for urothelial bladder cancer. World Journal of Urology, 2010, 28, 399-404.	2.2	45
25	Combinations of urine-based tumour markers in bladder cancer surveillance. Scandinavian Journal of Urology and Nephrology, 2009, 43, 461-466.	1.4	49
26	URINE-BASED TUMOR MARKER TESTS ARE A HELPFUL TOOL IN EARLY DIAGNOSIS OF BLADDER CANCER IN HIGH-RISK POPULATIONS – INTERIM DATA OF THE PROSPECTIVE STUDY UROSCREEN. Journal of Urology, 2008, 179, 325-325.	0.4	2